Board of Directors
Impressum
The content of this website has been carefully verified and Nitec takes seriously the need to ensure the website is updated when necessary. However, we make no absolute guarantees for completeness, correctness and most current up-to-datedness of any information contained in the website or accessible via embedded links.The copyright for www.nitecpharma.com is with Nitec Pharma AG.
This website is issued by:
Nitec Pharma AG
Kägenstrasse 17
CH-4153 Reinach
Switzerland
TEL: +41 61 715 20 40
FAX: +41 61 715 20 49
EMAIL: info@nitecpharma.com
Content Management and Web Programming:
College Hill – Life Sciences
Design:
KÄMPFERTEAM Markenagentur GmbH, Düsseldorf (Germany)
Photo on homepage by “mr. creank”, photocase.com
24/10/2007
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
Nitec Pharma to present 12-month efficacy and safety data for Lodotra™ at the annual meeting of the American College of Rheumatology in San Francisco
more
12/06/2008
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
Nitec to present Lodotra™ 12 month treatment data in Rheumatoid Arthritis at the Annual European Congress of Rheumatology (EULAR) in Paris.
more
22/01/2008
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
Nitec’s phase 3 results with Lodotra™ in RA published in current issue of The Lancet.
more
